CKD Stage 5 and ESRF Management

Definition and Diagnosis

• The American College of Radiology defines CKD Stage 5 as kidney failure with GFR <15 mL/min/1.73 m², requiring renal replacement therapy or conservative management 1, 2
• CKD Stage 5 is defined by GFR <15 mL/min/1.73 m², representing loss of more than 85% of kidney function according to KDIGO guidelines 2

Management Framework

• The American Journal of Kidney Diseases recommends that all patients with CKD Stage 4 (GFR <30 mL/min/1.73 m²) should be referred to nephrology for RRT planning when the risk of kidney failure within 1 year reaches 10-20% or higher 3, 4
• Referral must occur at least 1 year before anticipated RRT initiation to avoid "late referral" complications 3, 5
• Patients with progressive CKD Stage 5 require multidisciplinary care including dietary counseling, education about all RRT modalities, vascular access surgery planning, psychological and social support services, and conservative management counseling 3, 4, 6

Timing of Dialysis Initiation

• The American Journal of Kidney Diseases recommends that dialysis should be initiated based on clinical symptoms, not GFR alone, typically when one or more of the following are present: uremic symptoms, refractory fluid overload or uncontrolled hypertension, progressive malnutrition, severe electrolyte abnormalities, or uremic bleeding 3, 4, 6

Transplantation Considerations

• The American Journal of Kidney Diseases recommends that living donor preemptive renal transplantation should be considered when GFR <20 mL/min/1.73 m² with evidence of progressive, irreversible CKD over 6-12 months 3, 4

Conservative Management Option

• The American Journal of Kidney Diseases states that conservative management without RRT is a valid option and must be discussed with all CKD Stage 5 patients 3, 4, 5
• Conservative management is particularly appropriate for patients with multiple comorbidities, advanced age, or frailty 6

Medical Management in CKD Stage 5

• The American College of Cardiology recommends target BP <130/80 mmHg using ACE inhibitors or ARBs as first-line therapy 7
• Monitor serum creatinine and potassium within 5-7 days after initiating or adjusting doses 7
• Discontinue or reduce dose if creatinine rises >30% from baseline or potassium >5.5 mEq/L 7

Critical Pitfalls to Avoid

• Never rely solely on serum creatinine—always calculate eGFR using validated equations (MDRD or CKD-EPI) that account for age, sex, race, and body size 1, 2, 7
• Do not initiate dialysis based on GFR threshold alone without clinical symptoms, as early dialysis initiation does not improve outcomes 3, 4
• Avoid NSAIDs entirely in CKD Stage 5, as they worsen renal function and increase hyperkalemia risk 7
• Do not discontinue ACE inhibitors/ARBs prematurely when creatinine rises <30%, as initial rises are expected and do not indicate harm 7
• Never use thiazide diuretics when GFR <30 mL/min, as they are ineffective at this level of renal function 7

Prognosis

• CKD Stage 5 patients have extremely high cardiovascular mortality risk, with 3-year and 5-year survival rates on dialysis of only 55% and 40% respectively 2

Management of Advanced CKD (eGFR ≈ 15 mL/min/1.73 m²) – Evidence‑Based Recommendations

Nephrology Referral

Nutritional Management

Timing of Dialysis Initiation

Blood Pressure and Renin‑Angiotensin System Management

Monitoring Schedule

Dietary Sodium, Potassium, and Phosphorus Recommendations

Continuation of Renin‑Angiotensin System Blockade in Stage 5 Chronic Kidney Disease

KDIGO Guideline Recommendations

Monitoring and Safety Parameters

Management of Hyperkalemia Without Stopping RAS Blockade

Situations Requiring Adjustment of RAS Blockade

Guideline Recommendations for Pre‑Hemodialysis Assessment in Stage 5 CKD

Multidisciplinary Care

• Multidisciplinary management of CKD should incorporate dietary/nutritional counseling and psychological‑social support services for all patients with advanced kidney disease. 15

Transplantation Considerations

• Living‑donor pre‑emptive kidney transplantation is recommended when estimated GFR falls below 20 mL/min/1.73 m² and there is evidence of progressive, irreversible CKD over a 6–12‑month period. 15

Dialysis Initiation Criteria

• Initiation of dialysis must be based on the presence of uremic symptoms, refractory volume overload, uncontrolled hypertension, severe electrolyte abnormalities, or progressive malnutrition, rather than on a specific eGFR threshold alone. 15
• These clinical indications typically emerge when eGFR is between 5 and 10 mL/min/1.73 m²; starting dialysis at higher eGFR values in the absence of symptoms does not improve survival and may hasten loss of residual kidney function. 15

Conservative Management

• All patients with stage 5 CKD should be offered a discussion of conservative (non‑dialysis) management as a legitimate treatment option, especially those who are older, frail, or have multiple comorbidities. 15
• Conservative management programs should include structured protocols for symptom and pain control, psychological and spiritual care, and culturally sensitive end‑of‑life planning. 15

Medication Management in End‑Stage Renal Disease

Adjustments Required for Patients with Severe Kidney Impairment (eGFR < 15 mL/min/1.73 m²)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) should be avoided entirely because they aggravate renal dysfunction and raise the risk of hyperkalaemia in advanced CKD. 16
• Opioid analgesics must be used with extreme caution, with doses markedly reduced to prevent accumulation and toxicity in patients with eGFR < 15 mL/min/1.73 m². 16
• High‑dose benzylpenicillin (maximum 6 g/day) carries a risk of neurotoxicity in severe CKD; dosing should be limited accordingly. 16
• Tetracycline antibiotics can worsen uremia and therefore require dose reduction when kidney function falls below an eGFR of 45 mL/min/1.73 m². 16
• Metformin is contraindicated when eGFR < 30 mL/min/1.73 m² and should be discontinued in patients with advanced renal failure. [17] [18]